Evidence map›Paper›PMID 34118724›Full record

ReviewEuropean journal of medicinal chemistry2021

Improved SARS-CoV-2 M

Wayne Vuong, Conrad Fischer, Muhammad Bashir Khan, Marco J van Belkum, Tess Lamer, Kurtis D Willoughby, Jimmy Lu, Elena Arutyunova, Michael A Joyce, Holly A Saffran and 6 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European journal of medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 94 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Characterization of antiviral compounds using Bio-Layer Interferometry.bioRxiv : the preprint server for biology · 2025
    Article
  10. Article
  11. EfficientAntimicrobial agents and chemotherapy · 2025
    Article
  12. Review
  13. Article
  14. Article
  15. SARS-CoV-2 MSLAS discovery : advancing life sciences R & D · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Wayne VuongDepartment of Chemistry, University of Alberta, Edmonton AB, T6G 2G2, Canada.
Conrad FischerDepartment of Chemistry, University of Alberta, Edmonton AB, T6G 2G2, Canada.
Muhammad Bashir KhanDepartment of Biochemistry, Membrane Protein Disease Research Group, University of Alberta, Edmonton AB, T6G 2R3, Canada.
Marco J van BelkumDepartment of Chemistry, University of Alberta, Edmonton AB, T6G 2G2, Canada.
Tess LamerDepartment of Chemistry, University of Alberta, Edmonton AB, T6G 2G2, Canada.
Kurtis D WilloughbyDepartment of Chemistry, University of Alberta, Edmonton AB, T6G 2G2, Canada.
Jimmy LuDepartment of Biochemistry, Membrane Protein Disease Research Group, University of Alberta, Edmonton AB, T6G 2R3, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton AB, T6G 2E1, Canada.
Elena ArutyunovaDepartment of Biochemistry, Membrane Protein Disease Research Group, University of Alberta, Edmonton AB, T6G 2R3, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton AB, T6G 2E1, Canada.
Michael A JoyceDepartment of Medical Microbiology and Immunology, University of Alberta, Edmonton AB, T6G 2R3, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton AB, T6G 2E1, Canada.
Holly A SaffranDepartment of Medical Microbiology and Immunology, University of Alberta, Edmonton AB, T6G 2R3, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton AB, T6G 2E1, Canada.
Justin A ShieldsDepartment of Medical Microbiology and Immunology, University of Alberta, Edmonton AB, T6G 2R3, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton AB, T6G 2E1, Canada.
Howard S YoungDepartment of Biochemistry, Membrane Protein Disease Research Group, University of Alberta, Edmonton AB, T6G 2R3, Canada.
James A NiemanDepartment of Medical Microbiology and Immunology, University of Alberta, Edmonton AB, T6G 2R3, Canada; Li Ka Shing Applied Virology Institute, University of Alberta, Edmonton AB, T6G 2E1, Canada.
D Lorne TyrrellDepartment of Medical Microbiology and Immunology, University of Alberta, Edmonton AB, T6G 2R3, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton AB, T6G 2E1, Canada.
M Joanne LemieuxDepartment of Biochemistry, Membrane Protein Disease Research Group, University of Alberta, Edmonton AB, T6G 2R3, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton AB, T6G 2E1, Canada.
John C VederasDepartment of Chemistry, University of Alberta, Edmonton AB, T6G 2G2, Canada. Electronic address: john.vederas@ualberta.ca.
University of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Replication of SARS-CoV-2, the coronavirus causing COVID-19, requires a main protease (M

Indexed as

AnimalsAntiviral AgentsBinding SitesChlorocebus aethiopsCoronavirus 3C ProteasesCrystallography, X-RayCysteine Proteinase InhibitorsHumansLactamsLeucineMicellesMicrobial Sensitivity TestsMolecular StructureProtein BindingPyrrolidinesSARS-CoV-23C-like proteinase, SARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesCysteine Proteinase InhibitorsGC376LactamsLeucineMicellesPyrrolidinesSulfonic AcidsCOVID-19CrystallographyGC376 analogsMain proteaseProtease inhibitorStructure-guided design

Identifiers

PMID34118724
PMCPMC8164773
OpenAlexW3167205542

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.